Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma

Journal of Clinical Pathology

Volumn 66, Issue 11, 2013, Pages 956-961

  Frei, E ^a   Visco, C ^b   Xu Monette, Z Y ^c   Dirnhofer, S ^a   Dybkrae K ^d   Orazi, A ^e   Bhagat, G ^f   Hsi, E D ^g   Van Krieken, J H ^h   Ponzoni, M ⁱ   Go, R S ^j   Piris, M A ^k   Moller M B ^l   Young, Ken H ^c   Tzankov, Alexander ^a,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Department of Medicine   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^k HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^l ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; CYCLOPHOSPHAMIDE; DOXORUBICIN; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE SULFATE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY;

CELL CYCLE REGULATION; HAEMATOPATHOLOGY; LYMPHOMA;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLIN E; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PREDNISONE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84888294481     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201619     Document Type: Article

References (43)

1. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524-34.
2. Mitterlechner T, Fiegl M, Mühlböck H, et al. Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. J Clin Pathol 2006;59:48-55.
3. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
4. Fu K, Weisenburger DD, Choi WWL, et al. Addition of Rituximab to standard chemotherapy improves the survival of both germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-94.
5. Coiffier B, Lepage E, Brière J, et al. CHOP Chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42.
6. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61.
7. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
8. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-37.
9. Jais J-P, Haioun C, Molina TJ, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008;22:1917-24.
10. Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2011;118:4173-83.
11. Filipits M, Jaeger U, Pohl G, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002;8:729-33.
12. Erlanson M, Portin C, Linderholm B, et al. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998;92:770-7.
13. Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84.
14. Nagel S, Hirschmann P, Dirnhofer S, et al. Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. Exp Hematol 2010;38:38-45.
15. Hasselblom S, Ridell B, Sigurdardottir M, et al. Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma 2008;49:1501-9.
16. Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011;118:1350-8.
17. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995-1007.
18. Alevizopoulos K, Vlach J, Hennecke S, et al. Cyclin E and c-Myc promote cell proliferation in the presence of p16 INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J 1997;16:5322-33.
19. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
20. Mistrik M, Bartek J. Cyclin D3-dependent kinases in lymphoma: redundancy and implications for therapy. Cell Cycle 2010;9:446-47.
21. Spruck CH, Won K-A, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
22. Bakhoum SF, Danilova OV, Kaur P, et al. Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2011;17:7704-11.
23. Tzankov A, Gschwendtner A, Augustin A, et al. Diffuse large B-cell lymphoma with overexpression of cyclin E substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 2006;12:2125-32.
24. Nagel I, Akasaka T, Klapper W, et al. Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. Haematologica 2009;94:1020-3.
25. Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP consortium program study. Leukemia 2012;26:2103-13.
26. Cheson BD, Pfistner B, Juweid ME, et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
27. Stein H, Chan JKC, Warnke RA, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo Eeds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008:233-73.
28. Tzankov A, Zlobec I, Went P, et al. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010;51:199-212.
29. Mounier M, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
30. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
31. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996;87:265-72.
32. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;3:5137-44.
33. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709-23.
34. van Spronsen DJ, Vrints LW, Hofstra G, et al. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92. Br J Haematol 1997;96:322-7.
35. Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842-7.
36. Copie-Bergman C, Gaulard P, Leroy K, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009;27:5573-9.
37. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070-8.
38. Li ZM, Huang JJ, Xia Y, et al. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Eur J Haematol 2012;88:510-17.
39. Gladden AB, Diehl JA. Cell cycle progression without cyclin E/CDK2: breaking down the walls of dogma. Cancer Cell 2003;4:160-2.
40. Taji H, Kagami Y, Okada Y. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998;89:748-56.
41. Harjunpää A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51:634-41.
42. Kanzaki M, Shibata H, Mogami H, et al. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in balb/c 3T3 cells. J Biol Chem 1995;270:13099-104.
43. Bubien JK, Zhou LJ, Bell PD, et al. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993;121:1121-32.